Limits...
Effects of febuxostat on platelet-derived microparticles and adiponectin in patients with hyperuricemia.

Nishizawa T, Taniura T, Nomura S - Blood Coagul. Fibrinolysis (2015)

Bottom Line: Levels of PDMP and biomarkers were measured using an ELISA at baseline and after 2 and 6 months of treatment.Uric acid and interleukin (IL)-6 levels decreased significantly in hyperuricemic patients after 2 months of febuxostat treatment.These results suggest that the effects of febuxostat for PDMPs seen may be the effect on xanthine oxidase but not the decrease of uric acid, and febuxostat may be beneficial for primary prevention of atherothrombosis in hyperuricemic patients.

View Article: PubMed Central - PubMed

Affiliation: aFirst Department of Internal Medicine, Kansai Medical University, Osaka bDivision of Internal Medicine, Daiwa Hospital, Japan.

ABSTRACT
Platelet-derived microparticles (PDMPs) and adiponectin play an important role in the development of atherothrombosis. We investigated the effect of febuxostat on circulating PDMP levels and adiponectin in hyperuricemic patients. Levels of PDMP and biomarkers were measured using an ELISA at baseline and after 2 and 6 months of treatment. Plasma levels of PDMPs and biomarkers were higher, while those of adiponectin were lower in hyperuricemic patients than in normouricemic controls. Uric acid and interleukin (IL)-6 levels decreased significantly in hyperuricemic patients after 2 months of febuxostat treatment. However, PDMP and biomarkers decreased significantly in hyperuricemic patients after only 6 months of febuxostat treatment and adiponectin increased significantly. These results suggest that the effects of febuxostat for PDMPs seen may be the effect on xanthine oxidase but not the decrease of uric acid, and febuxostat may be beneficial for primary prevention of atherothrombosis in hyperuricemic patients.

Show MeSH

Related in: MedlinePlus

Changes in the plasma levels of monocyte chemoattractant protein-1 (MCP-1), adiponectin, sE-selectin and soluble vascular cell adhesion molecule-1 (sVCAM-1) before and after febuxostat treatment in hyperuricemic patients. Data are shown as mean ± SD. P value, 0 vs. 2 or 6 months. N.S., not significant.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4664023&req=5

Figure 2: Changes in the plasma levels of monocyte chemoattractant protein-1 (MCP-1), adiponectin, sE-selectin and soluble vascular cell adhesion molecule-1 (sVCAM-1) before and after febuxostat treatment in hyperuricemic patients. Data are shown as mean ± SD. P value, 0 vs. 2 or 6 months. N.S., not significant.

Mentions: Uric acid and IL-6 levels decreased significantly in hyperuricemic patients after 2 and 6 months of febuxostat treatment (Fig. 1). However, PDMP, sP-selectin, MCP-1, sE-selectin and sVCAM-1 decreased significantly in hyperuricemic patients after only 6 months of febuxostat treatment and adiponectin increased significantly (Fig. 1 and 2). On the contrary the enhancing effect of uric acid on PDMPs was not observed in an in-vitro experiment using platelet-rich plasma of healthy persons (Fig. 3).


Effects of febuxostat on platelet-derived microparticles and adiponectin in patients with hyperuricemia.

Nishizawa T, Taniura T, Nomura S - Blood Coagul. Fibrinolysis (2015)

Changes in the plasma levels of monocyte chemoattractant protein-1 (MCP-1), adiponectin, sE-selectin and soluble vascular cell adhesion molecule-1 (sVCAM-1) before and after febuxostat treatment in hyperuricemic patients. Data are shown as mean ± SD. P value, 0 vs. 2 or 6 months. N.S., not significant.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4664023&req=5

Figure 2: Changes in the plasma levels of monocyte chemoattractant protein-1 (MCP-1), adiponectin, sE-selectin and soluble vascular cell adhesion molecule-1 (sVCAM-1) before and after febuxostat treatment in hyperuricemic patients. Data are shown as mean ± SD. P value, 0 vs. 2 or 6 months. N.S., not significant.
Mentions: Uric acid and IL-6 levels decreased significantly in hyperuricemic patients after 2 and 6 months of febuxostat treatment (Fig. 1). However, PDMP, sP-selectin, MCP-1, sE-selectin and sVCAM-1 decreased significantly in hyperuricemic patients after only 6 months of febuxostat treatment and adiponectin increased significantly (Fig. 1 and 2). On the contrary the enhancing effect of uric acid on PDMPs was not observed in an in-vitro experiment using platelet-rich plasma of healthy persons (Fig. 3).

Bottom Line: Levels of PDMP and biomarkers were measured using an ELISA at baseline and after 2 and 6 months of treatment.Uric acid and interleukin (IL)-6 levels decreased significantly in hyperuricemic patients after 2 months of febuxostat treatment.These results suggest that the effects of febuxostat for PDMPs seen may be the effect on xanthine oxidase but not the decrease of uric acid, and febuxostat may be beneficial for primary prevention of atherothrombosis in hyperuricemic patients.

View Article: PubMed Central - PubMed

Affiliation: aFirst Department of Internal Medicine, Kansai Medical University, Osaka bDivision of Internal Medicine, Daiwa Hospital, Japan.

ABSTRACT
Platelet-derived microparticles (PDMPs) and adiponectin play an important role in the development of atherothrombosis. We investigated the effect of febuxostat on circulating PDMP levels and adiponectin in hyperuricemic patients. Levels of PDMP and biomarkers were measured using an ELISA at baseline and after 2 and 6 months of treatment. Plasma levels of PDMPs and biomarkers were higher, while those of adiponectin were lower in hyperuricemic patients than in normouricemic controls. Uric acid and interleukin (IL)-6 levels decreased significantly in hyperuricemic patients after 2 months of febuxostat treatment. However, PDMP and biomarkers decreased significantly in hyperuricemic patients after only 6 months of febuxostat treatment and adiponectin increased significantly. These results suggest that the effects of febuxostat for PDMPs seen may be the effect on xanthine oxidase but not the decrease of uric acid, and febuxostat may be beneficial for primary prevention of atherothrombosis in hyperuricemic patients.

Show MeSH
Related in: MedlinePlus